Acquisition of MorphoSys by Novartis Closed

Public Takeover Offer by Novartis:

On February 5, 2024, MorphoSys entered into a Business Combination Agreement with Novartis BidCo AG (formerly known as Novartis data42 AG) and Novartis AG (hereinafter collectively referred to as “Novartis”) based on the intention of Novartis to submit a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares. Novartis offered MorphoSys shareholders 
€ 68.00 per share in cash, representing a total equity value of € 2.7 billion (the “Takeover Offer”).

On April 11, 2024, Novartis submitted its Takeover Offer to MorphoSys shareholders. The acceptance period of the Takeover Offer ended on May 13, 2024. The settlement of the shares tendered during the acceptance period and the change of control occurred on May 23, 2024. The statutory two-week additional acceptance period ended on May 30, 2024. The settlement of the shares tendered during the additional acceptance period occurred on June 10, 2024.

As of June 20, 2024, Novartis holds approximately 91.04% of the total MorphoSys share capital, including purchases by Novartis outside of the Takeover Offer. As a result, Novartis is the majority shareholder of MorphoSys, making MorphoSys a Novartis company.

Delisting Purchase Offer by Novartis:

On June 20, 2024, MorphoSys and Novartis signed a delisting agreement confirming that Novartis intends to launch a public delisting purchase offer (the “Delisting Offer”) for all outstanding MorphoSys no-par value bearer shares that are not presently held by Novartis. Novartis offers MorphoSys shareholders € 68.00 per share in cash, corresponding to its preceding Takeover Offer.

On July 4, 2024, Novartis published its Delisting Offer document following approval by the German Federal Financial Supervisory Authority (“BaFin”). With the publication of the offer document, the acceptance period has commenced and will expire on August 2, 2024, at 24:00 hours CEST and 18:00 hours EDT. The Novartis Delisting Offer document is available here.

The MorphoSys Management Board and Supervisory Board have published a joint reasoned statement unanimously recommending its shareholders to accept the Delisting Offer. The MorphoSys joint reasoned statement on the Delisting Offer is available here.

Now that the Novartis Delisting Offer document has been published, MorphoSys will apply for revocation of the admission to trading of MorphoSys shares on the regulated market of the Frankfurt Stock Exchange. On July 12, 2024, MorphoSys also formally notified Nasdaq of its intention to delist its American Depositary Shares (“ADSs”). 

After the delisting becomes effective, MorphoSys shares and ADSs will no longer be traded on the regulated market of the Frankfurt Stock Exchange or on Nasdaq, and follow-up obligations from such a public listing will no longer apply. Additionally, following deregistration with the U.S. Securities and Exchange Commission (the "SEC"), MorphoSys will no longer be required to file reports with the SEC. The delisting from the Frankfurt Stock Exchange is expected to take place in August 2024. The last trading day of the ADSs on the Nasdaq is expected to be on or about August 2, 2024.

Merger Squeeze-out:

On June 20, 2024, Novartis BidCo Germany AG, an indirect 100% subsidiary of Novartis, also informed MorphoSys of their intention to merge MorphoSys into Novartis BidCo Germany AG. In this context, Novartis BidCo Germany AG has proposed entering negotiations with the MorphoSys Management Board regarding a merger agreement. The conclusion and notarization of the merger agreement between MorphoSys AG and Novartis BidCo Germany AG will take place soon.

As Novartis BidCo Germany AG holds approximately 91.04% and, after deduction of the number of treasury shares, approximately 91.17% of MorphoSys’ total share capital, Novartis BidCo Germany AG is able to facilitate a squeeze-out of MorphoSys’ minority shareholders in connection with the merger. To this end, on July 12, 2024, Novartis BidCo Germany AG submitted a specified request (konkretisiertes Verlangen) to the MorphoSys Management Board to convene the MorphoSys Annual General Meeting to resolve this topic. At the MorphoSys Annual General Meeting, expected to take place on August 27, 2024, a resolution will be adopted on transferring MorphoSys’ minority shareholder shares to Novartis BidCo Germany AG against a cash compensation of € 68.00 per share. The court-appointed expert auditor has confirmed the cash compensation to be adequate.

The merger squeeze-out will become effective once it has been approved by the MorphoSys Annual General Meeting, the transfer resolution and merger have been registered in the commercial register of MorphoSys AG, and the merger has been registered in the commercial register of Novartis BidCo Germany AG. 

Public Communications:  

Additional Information and Where to Find It

This communication is neither an offer to purchase nor a solicitation of an offer to sell shares of MorphoSys AG (the “Company”). Following approval by the German Federal Financial Supervisory Authority (the “BaFin”), Novartis BidCo AG (the “Bidder”) has published an offer document containing the final terms and further provisions regarding the offer to purchase all outstanding Company no-par value bearer shares, including all no-par value bearer shares represented by American Depositary Shares, at an offer price of € 68.00 per share in cash (the “Delisting Offer”). The Bidder and Novartis AG have also filed with the U.S. Securities and Exchange Commission (the “SEC”) a Tender Offer Statement on Schedule TO containing the offer document, the means to tender and other related documents (together, the “Delisting Offer Documents”). The Delisting Offer is being made solely pursuant to the Delisting Offer Documents, which contain the full terms and provisions of the Delisting Offer. The Company’s management board and supervisory board have issued a joint reasoned statement in accordance with sec. 27 of the German Securities Acquisition and Takeover Act and the Company has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC (together with the joint reasoned statement, the “Recommendation Statements”). THE COMPANY’S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE DELISTING OFFER DOCUMENTS AND THE RECOMMENDATION STATEMENTS, AS WELL AS OTHER DOCUMENTS FILED WITH THE SEC, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION WHICH SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE DELISTING OFFER. The Tender Offer Statement on Schedule TO and the Solicitation/Recommendation Statement on Schedule 14D-9 are available for free at the SEC’s website at Additional copies may be obtained for free by contacting the Bidder or the Company. Free copies of these materials and certain other offering documents are available on the Company’s website in English at and in German at, by mail to MorphoSys AG, Semmelweisstrasse 7, 82152 Planegg, Germany or by phone at +49 89 8992 7179.

In addition to the Delisting Offer Documents and the Recommendation Statements, the Company files other information with the SEC. The Company’s filings with the SEC are also available for free to the public from commercial document-retrieval services and at the website maintained by the SEC at and are also available free of charge under the “SEC Filings” section of the Company’s website at

In order to reconcile certain areas where German law and U.S. law conflict, Novartis AG and the Bidder obtained no-action and exemptive relief from the SEC to conduct the Delisting Offer in the manner described in the Delisting Offer Documents.

Acceptance of the Delisting Offer by stockholders residing outside Germany and the United States of America may be subject to further legal requirements. With respect to the acceptance of the Delisting Offer outside Germany and the United States, no responsibility is assumed for the compliance with such legal requirements applicable in the respective jurisdiction.

Forward-Looking Statements

This communication contains certain forward-looking statements concerning the Company, the Bidder and the Delisting Offer that involve substantial risks and uncertainties. Forward-looking statements include any statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “goal,” “may,” “might,” “plan,” “predict,” “project,” “seek,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” and similar expressions. In this communication, the Company’s forward-looking statements include statements about the expected timetable for the consummation of the Delisting Offer and the delisting; the Company’s plans, objectives, expectations and intentions; and the financial condition, results of operations and business of the Company and Novartis AG.

The forward-looking statements contained in this communication represent the judgment of the Company as of the date of this communication and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of the Company, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if the Company's results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: uncertainties as to how many of the Company’s stockholders will tender their stock in the Delisting Offer; the possibility that competing offers will be made;  the effects of the acquisition of MorphoSys by Novartis AG on relationships with employees, other business partners or governmental entities; that the Bidder and Novartis AG may not realize the potential benefits of the acquisition of MorphoSys by Novartis AG; transaction costs associated with the Delisting Offer; potential operational difficulties with integrating MorphoSys with Novartis AG; that the Company’s expectations may be incorrect; the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements; the Company's reliance on collaborations with third parties; estimating the commercial potential of the Company’s development programs; and other risks indicated in the risk factors included in the Company’s filings with the SEC, including the Company’s Annual Report on Form 20-F, as well as the Solicitation/Recommendation Statement on Schedule 14D-9 to be filed by the Company and the Tender Offer Statement on Schedule TO and related Delisting Offer documents to be filed by the Bidder and Novartis AG. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this communication. The Company and the Bidder expressly disclaim any obligation to update any such forward-looking statements in this communication to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.